SYK is the ticker symbol for STRYKER CORP, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks SYK with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is SYK a good stock to buy?

13F Pro's AI ranking engine scores SYK at 72.1/100, ranked #162 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for SYK is available at https://13fpro.ai/company/SYK. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source SYK data?

All STRYKER CORP fundamentals and ownership data come directly from SEC EDGAR. STRYKER CORP files with the SEC under CIK 310764. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

STRYKER CORP SYK

NYSELarge CapHealthcare

13F Pro quality score

Rank #162 of 2,925TOP 10%

Why it scores 72 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$6.59B

Quarter to Jun 30

Net income

$1.28B

Quarter to Jun 30

Free cash flow

$1.06B

Quarter to Jun 30

Operating margin

25.2%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$97.09B total

BlackRock, Inc.

$8.63B-0.7%

VANGUARD CAPITAL MANAGEMENT LLC

$7.10B+0.7%

JPMORGAN CHASE & CO

$5.71B+10.7%

STATE STREET CORP

$4.90B+1.2%

GREENLEAF TRUST

$4.79B-4.5%

PRICE T ROWE ASSOCIATES INC /MD/

$3.75B+18.7%

VANGUARD PORTFOLIO MANAGEMENT LLC

$2.57B-1.9%

WELLINGTON MANAGEMENT GROUP LLP

$2.57B+0.6%

GEODE CAPITAL MANAGEMENT, LLC

$2.45B+0.9%

MORGAN STANLEY

$1.88B-5.3%

ALLIANCEBERNSTEIN L.P.

$1.62B-18.6%

NORGES BANK

$1.54B--

BANK OF AMERICA CORP /DE/

$1.40B+8.4%

Bank of New York Mellon Corp

$1.12B-10.2%

ROYAL BANK OF CANADA

$1.09B+6.2%

NORTHERN TRUST CORP

$1.05B+0.7%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$1.03B+111.0%

AMERIPRISE FINANCIAL INC

$1.03B+132.6%

First Western Trust Bank

$949.98M-0.1%

Fundsmith LLP

$917.39M-4.8%

FRANKLIN RESOURCES INC

$877.71M+0.1%

GOLDMAN SACHS GROUP INC

$876.45M+4.3%

UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AME

$846.72M+21.8%

WELLS FARGO & COMPANY/MN

$758.03M+4.8%

Legal & General Group Plc

$707.21M-5.4%

See all 2,274 institutional holders →

What's Driving SYK's Business? Latest 10-Q Breakdown

34/34 datapoints verified

AI-extracted from the 10-Q filed 2026-07-31 — Q2 2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 9.4% to $6,589M while a $158M reversal of 2025 tariffs helped lift gross margin to 68.3% and operating margin to 25.2%.

Biggest Revenue Drivers

MedSurg and Neurotechnology$3,625M+9.7% YoY

Up 9.2% in constant currency, 9.1% from unit volume and 0.1% from higher prices across most businesses

Orthopaedics$2,964M+9.1% YoY

Constant currency up 8.7%; excluding acquisitions/divestitures up 8.6% from higher shipments across all Orthopaedics businesses

Biggest Revenue Drivers

Total revenue: $6.6B+9.4% YoY

MedSurg and Neurotechnology$3,625M+9.7% YoY

Up 9.2% in constant currency, 9.1% from unit volume and 0.1% from higher prices across most businesses

Within MedSurg and Neurotechnology

Medical$1,122M+13.4% YoY

United States sales up 12.6%, international up 17.9%

Vascular$496M-0.7% YoY

Down 1.8% in constant currency, with United States sales down 6.7%

Orthopaedics$2,964M+9.1% YoY

Constant currency up 8.7%; excluding acquisitions/divestitures up 8.6% from higher shipments across all Orthopaedics businesses

Within Orthopaedics

Trauma and Extremities$1,072M+11.9% YoY

United States sales up 12.5%, international up 10.3%

Largest Expense Items

Selling, general and administrative$2,229M+7.2% YoY

Fell to 33.8% of sales from 34.5% on spend discipline and lower acquisition and integration-related charges, offset by structural optimization charges

Cost of sales$2,091M-4.1% YoY

Benefited from reduction of certain import tariffs and lower amortization of inventory stepped up to fair value

Research, development and engineering$434M+6.6% YoY

6.6% of net sales, relatively flat with 6.8% in 2025

Amortization of intangible assets$175M-6.4% YoY

Margins: Gross margin rose to 68.3% from 63.8%, driven by a reversal of 2025 tariffs (260 bps) and lower inventory step-up amortization (110 bps). Operating margin reached 25.2% versus 18.5%.

Watch Items from the Filing

A $158M reversal of 2025 tariffs added 260 bps to gross margin and $0.34 to diluted EPS; management excludes it from adjusted results.
Vascular sales fell 0.7% to $496M (-1.8% constant currency), with United States Vascular down 6.7% — the only declining business.
Cybersecurity incident first reported March 11, 2026 caused idle production time raising manufacturing costs; forward-looking statements cite continuing uncertainty on operations and results.
Structural optimization and other special charges rose to $95M from $11M, including $70M of 'other charges' in the quarter.
Level 3 contingent consideration grew to $756M from $518M, including $271M from the AVS acquisition with up to $400M future milestones.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q2 2026

EDGAR

Net Income

Q2 2026

EDGAR

EPS (Diluted)

Q2 2026

EDGAR

Operating Margin

Q2 2026

EDGAR

ROIC

Q2 2026

EDGAR

Free Cash Flow

Q2 2026

EDGAR

Debt/Equity

Q2 2026

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/SYK

Earnings Per Share

13fpro.ai/company/SYK

Loading ratio trend…

STRYKER CORP reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2025	10-K	$25.1B	$3.2B	19.5%
FY 2024	10-K	$22.6B	$3.0B	16.3%
FY 2023	10-K	$20.5B	$3.2B	19.0%
FY 2022	10-K	$18.4B	$2.4B	15.4%
FY 2021	10-K	$17.1B	$2.0B	15.1%
FY 2020	10-K	$14.4B	$1.6B	15.5%

About STRYKER CORP (SYK): stock profile, AI score and financials

STRYKER CORP (SYK) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SYK at 72.1/100 on a composite quality score built from its SEC filings, placing it at rank #162 of 2,925 stocks — the top 10% of the AI-ranked universe. SYK scores in the top quartile across revenue scale (94.0), balance sheet strength (80.2). Based on the latest XBRL financial filings (Q2 2026), STRYKER CORP reports quarterly revenue of $6.6B, net income of $1.3B, an operating margin of 25.2%. Top institutional holders of SYK by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, JPMORGAN CHASE, based on the most recent SEC filings. SYK trades on the NYSE exchange and files with the SEC under CIK 310764. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SYK daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STRYKER CORP directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 310764 →

STRYKER CORP SYK

Top Institutional Holders

What's Driving SYK's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

SYK key financials by period

SYK insiders

Congress trading in SYK

About STRYKER CORP (SYK): stock profile, AI score and financials

STRYKER CORP SYK

Top Institutional Holders

What's Driving SYK's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

SYK key financials by period

Companies similar to SYK

SYK insiders

Congress trading in SYK

About STRYKER CORP (SYK): stock profile, AI score and financials